Advicenne Hastens EU Approval For Sibnayal By Withdrawing Orphan Designation
Advicenne withdrew its orphan drug designation application for Sibnayal over concerns that a key study was not designed to compare the product with the standard of care.
You may also be interested in...
More should be done to incentivize comparative clinical trials so as to allow better decisions on drug pricing to be taken, said Austria’s representative at a recent meeting of EU health ministers.
Five Nordic countries are agreeing a common strategy for closer collaboration on access to hospital drugs.
Shionogi and Pfizer have formally agreed to a scheme that offers companies a new and sustainable payment model for innovating in antibiotics.